Ad-hoc | 24 February 2005 10:05

STRATEC Biomedical Systems AG: 2004 results significantly above target

Ad hoc announcement §15 WpHG Preliminary results for the 2004 financial year STRATEC Biomedical Systems AG: 2004 results significantly above target Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— STRATEC’s 2004 results significantly above target – Disproportionate increase of 62.4% in annual net income to reach Euro 2.735 million – Sales grow by 27.7% to Euro 40.442 million – EBIT margin now in double digits – Proposed dividend raised by 87.5% to Euro 0.15 per share Birkenfeld, February 24, 2005 The Board of Management of STRATEC Biomedical Systems AG, listed in the German Prime Standard and Gate-M segments, hereby announces its preliminary unaudited results for the 2004 financial year pursuant to IFRS (International Financial Reporting Standards) and in line with Section 15 of the German Securities Trading Act (WpHG). Key Figures (Euro 000s) 2004 2003 Change Sales 40,442 31,662 + 27.7% Overall performance 39,207 32,807 + 19.5% EBITDA 5,642 3,987 + 41.5% EBIT 4,638 3,039 + 52.6% EBT 4,395 2,771 + 58.6% Annual net income 2,735 1,684 + 62.4% Earnings per share (Euro) 0.83 0.51 + 62.7% STRATEC Biomedical Systems had a total of 173 employees as of December 31, 2004 (previous year: 154). The Board of Management will propose the payment of a dividend amounting to Euro 0.15 for the 2004 financial year (previous year: Euro 0.08) for approval by the Supervisory Board. The Annual General Meeting to be held on May 4, 2005 will pass resolution on the dividend thereby proposed by the company’s management. STRATEC Biomedical Systems AG Gewerbestraße 37 75217 Birkenfeld Deutschland ISIN: DE0007289001 WKN: 728900 Listed: Geregelter Markt in Frankfurt (Prime Standard) und Stuttgart; Freiverkehr in Berlin-Bremen, Düsseldorf und München End of ad hoc announcement (c)DGAP 24.02.2005 Issuer’s information/explanatory remarks concerning this ad hoc announcement: The preliminary unaudited earnings figures published by STRATEC Biomedical Systems AG for the 2004 financial year are considerably in excess of all analysts’ forecasts available to the company. The definitive figures for the 2004 financial year will be commented on in the Annual Press Conference Call to be held on March 31, 2005. Press representatives, investors and analysts wishing to take part in this telephone conference are kindly requested to register with our Investor Relations Team (Tel: +49 (0)7082 7916-190). About STRATEC Biomedical Systems AG STRATEC (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems together with their own reagents to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (WKN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the Gate-M trading segment of the Stuttgart Stock Exchange and on other exchanges. Further information can be obtained from: STRATEC Biomedical Systems AG Investor Relations André Loy Gewerbestrasse 37 75217 Birkenfeld Germany Tel: +49 (0)7082 7916-190 Fax: +49 (0)7082 7916-999 E-Mail: ir@stratec-biomedical.de End of message (c)DGAP 241005 Feb 05